| Breast Cancer |
1 |
1 |
| Menopause |
0 |
0.83 |
| Estrogen |
0 |
0.78 |
| Cancer |
0 |
0.51 |
| Ovarian Cancer |
0 |
0.46 |
| Cancer Risk |
0 |
0.41 |
| Vaginal Cancer |
0 |
0.39 |
| Lung Cancer |
0 |
0.32 |
| Contraception |
0 |
0.29 |
| Genomic Medicine |
0 |
0.29 |
| Breast |
0 |
0.25 |
| Ovary |
0 |
0.17 |
| Vagina |
0 |
0.17 |
| Atrophic Vaginitis |
0 |
0.15 |
| Progestin |
0 |
0.12 |
| Aesthetic Medicine |
0 |
0.11 |
| Hormonal Therapy |
0 |
0.1 |
| Hysterectomy |
0 |
0.1 |
| Thromboembolism |
0 |
0.1 |
| Uterus |
0 |
0.1 |
| Sterilization, Birth Control |
0 |
0.09 |
| Birth |
0 |
0.08 |
| Hormonal Contraception |
0 |
0.08 |
| Surgery |
0 |
0.08 |
| Transdermal |
0 |
0.08 |
| Bilateral Mastectomy |
0 |
0.07 |
| Gynecologic Surgery |
0 |
0.07 |
| Osteoporosis |
0 |
0.07 |
| Bone |
0 |
0.05 |
| BRCA |
0 |
0.05 |
| Dysfunctional Uterine Bleeding |
0 |
0.05 |
| Genetics |
0 |
0.05 |
| Insurance |
0 |
0.05 |
| Mastectomy |
0 |
0.05 |
| Generics |
0 |
0.04 |
| Revenue and Practice Management |
0 |
0.04 |
| Skin and Soft Tissue Infection |
0 |
0.04 |
| Vaginitis |
0 |
0.04 |
| Venous Thromboembolism (VTE) |
0 |
0.04 |
| Adenomyosis |
0 |
0.03 |
| Florida |
0 |
0.03 |
| Geriatrics |
0 |
0.03 |
| Hypertension |
0 |
0.03 |
| Oophorectomy |
0 |
0.03 |
| Anxiety |
0 |
0.02 |
| Bisphosphonate |
0 |
0.02 |
| Blood |
0 |
0.02 |
| Cardiovascular disease |
0 |
0.02 |
| Cardiovascular Risk Management |
0 |
0.02 |
| Chemotherapy |
0 |
0.02 |
| Chronic Disease |
0 |
0.02 |
| Dementia |
0 |
0.02 |
| Dyslipidemia |
0 |
0.02 |
| Dyspareunia |
0 |
0.02 |
| Grant |
0 |
0.02 |
| Heart |
0 |
0.02 |
| Lung |
0 |
0.02 |
| Medical Oncology |
0 |
0.02 |
| Metabolism |
0 |
0.02 |
| Night Sweats |
0 |
0.02 |
| Ovarian Insufficiency |
0 |
0.02 |
| Pollex |
0 |
0.02 |
| Radiation Therapy |
0 |
0.02 |
| Sexuality |
0 |
0.02 |
| Ultrasonography |
0 |
0.02 |
| Anxiety Disorder |
0 |
0.01 |
| Hypogonadism |
0 |
0.01 |
| Infertility Female |
0 |
0.01 |
| Lipids Management |
0 |
0.01 |
| Sexual Dysfunction in Female |
0 |
0.01 |